Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI from Underperform to Hold and doubled its price target to $70 from $35, citing accelerating Data and Applications growth and strategic collaborations; the stock was trading at $78.48 after gaining 43% over six months. The firm noted execution risks around the PSNL deal, slowing Ambry growth, reimbursement, and 2027 margins, and said at 8x 2027 sales further multiple expansion would require stronger proof points. Separately, Tempus reported Q3 2026 revenue of $411.5 million, up 23% year over year, adjusted EPS of $0.07 versus $0.01 expected, and positive adjusted EBITDA of $25.6 million; it raised full-year revenue guidance to $1.60 billion–$1.605 billion.

Analysis

The key debate is whether Tempus can turn data growth into durable, high-quality economics—not whether the collaboration pipeline sounds attractive. Strategic deals can validate the platform, but they are not proof of recurring, high-margin revenue; verify contract duration, revenue recognition, customer concentration, and renewal or expansion rates before underwriting them. Bristol Myers Squibb may gain access to differentiated data, while Tempus’s bargaining power depends on demonstrating that the data improves customer outcomes enough to support repeat spend. Deal economics and concentration are not provided.

At 8x 2027 sales, the setup is vulnerable to even modest slippage in growth or integration: a positive adjusted EBITDA quarter is encouraging, but does not establish cash conversion or durable consolidated profitability. The cited PSNL integration costs, Ambry growth, and reimbursement exposure are potential sources of estimate revisions. xR/xF regulatory progress could reduce product-access uncertainty, but FDA clearance alone would not establish reimbursement or adoption; xT’s 2027 ASP benefit is a later catalyst, not a near-term earnings offset.

Over days, momentum and differing analyst targets may support the shares, but the upgrade itself offers limited valuation headroom relative to the quoted market price. Over 1–3 months, watch guidance, segment growth, acquisition unit economics, and cash conversion. Over 6–18 months, the bull case requires repeatable data monetization and successful integration. Contrarian risk: investors may be treating bookings, partnerships, regulatory milestones, and adjusted EBITDA as interchangeable proof of scalable economics. The thesis weakens if data growth decelerates, guidance is cut, integration drag persists, or reimbursement progress fails to translate into utilization.

Key Decisions for Investors

• Do not chase TEM solely on the analyst upgrade. For existing exposure, consider trimming into strength or keeping sizing disciplined until reported data-segment growth converts into repeat customer spending and cash generation.
• Treat TEM as a catalyst-driven watch rather than an outright short: consider a defined-risk put spread only if option pricing is reasonable and ahead of an identifiable earnings or regulatory catalyst; otherwise avoid paying an unknown volatility premium.
• Before adding, verify PSNL deal contribution and unit economics, Ambry growth, segment-level guidance, cash conversion, and the commercial terms and concentration of major collaborations. A guidance reduction or persistent integration drag would falsify the execution thesis.
• Track FDA milestones separately from reimbursement and adoption evidence for xR/xF; clearance without coverage or utilization would not validate the projected commercial upside.